Your gateway to a free society
Article

Why Mises’s Theory of Economic Calculation Still Is Relevant Today

Back

aboutLiberty Portal

Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Mar 20, 2026 / Tyler Durden
Qatar Dethroned As 'LNG King' As U.S. Seizes Throne, Reshaping Future Of Gas
Qatar Dethroned As 'LNG King' As U.S. Seizes Throne, Reshaping Future Of Gas Submitted by Criterion Research President, James Bevan,  The geopolitical calculus underpinning global LNG supply through the early 2030s has shifted materially. Iranian drone strikes on Qatari LNG trains, delays to key expansion projects, and the indefinite closure of the Strait of Hormuz have created a compounding threat to Qatar's LNG position that goes well beyond a construction delay. What had been framed as a two-horse race for global LNG market share now looks considerably more one-sided. The beneficiary is clear: U.S. Gulf...
Read more
Apr 22, 2026 / Tyler Durden
U.S. Gov't Could End Up Owning 90% Of Spirit In Rescue Deal
U.S. Gov't Could End Up Owning 90% Of Spirit In Rescue Deal Summary: WSJ says the Trump administration's possible $500 million rescue deal could leave the U.S. government with 90% control. WSJ says Commerce Secretary Howard Lutnick is leading the effort in U.S.-Spirit talks. BBG reported earlier on a potential $500 million rescue loan for Spirit. News of a possible rescue loan for Spirit emerged last week. Polymarket:  US takes a stake in Spirit Airlines by May 31? Yes 36% · No 64%View full market & trade on Polymarket Spirit Airlines shutdown/liquidation by May 31? Yes...
Read more
Feb 23, 2026 / Tyler Durden
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound). Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug." Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...
Read more

support

If you like what we do and want to support us, then you are a fine humanitarian. Click the link below to find out more.

Support the liberty movement